The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ ...

In recent decades, the incidence of some hematological malignancies (HMs), such as acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML), has decreased, while the incidence of others ...

The Hematological Genetics lab is led by Drs Outi Kilpivaara (geneticist) and Ulla Wartiovaara-Kautto (clinical hematologist). Our research stems from the intriguing curiosity towards mechanisms of ...

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ...

JMP Securities analyst Silvan Tuerkcan has reiterated their bullish stance on VOR stock, giving a Buy rating on November 8. Silvan ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports ...

Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdom, (GLOBE ...

A disease historically associated with malnourishment on sailing vessels may have a new, modern culprit: Bariatric surgery.

Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s ...

HC Wainwright reaffirmed their buy rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research note issued to investors on Friday,Benzinga reports. The firm currently has a $17.50 price ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports ...

Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a ...